Joanna Horobin Net Worth

The estimated Net Worth of Joanna Horobin is at least $144 Tausend dollars as of 7 June 2024. Joanna Horobin owns over 8,500 units of Liquidia Corp stock worth over $86,275 and over the last 12 years he sold LQDA stock worth over $0. In addition, he makes $57,450 as Independent Director at Liquidia Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Joanna Horobin LQDA stock SEC Form 4 insiders trading

Joanna has made over 3 trades of the Liquidia Corp stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 8,500 units of LQDA stock worth $17,680 on 7 June 2024.

The largest trade he's ever made was exercising 8,500 units of Liquidia Corp stock on 7 June 2024 worth over $17,680. On average, Joanna trades about 398 units every 144 days since 2012. As of 7 June 2024 he still owns at least 8,500 units of Liquidia Corp stock.

You can see the complete history of Joanna Horobin stock trades at the bottom of the page.

Joanna Horobin biography

Dr. Joanna C. Horobin M.D. serves as Independent Director of the Company. Dr. Horobin served as the Senior Vice President and Chief Medical Officer of Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the clinical development, and ultimately the commercialization, of drug candidates for both oncology and rare disease indications (“Idera”) (Nasdaq: IDRA), from November 2015 until July 2019. Prior to joining Idera, Dr. Horobin served as the Chief Medical Officer of Verastem, Inc. (“Verastem”) (Nasdaq: VSTM), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, from September 2012 to July 2015. Prior to joining Verastem, she served as President of Syndax Pharmaceuticals, Inc. (“Syndax”) (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, from September 2006 to September 2012 and as Chief Executive Officer from September 2006 until April 2012. Prior to that, Dr. Horobin held several roles of increasing responsibility at global pharmaceutical corporations such as Rhône-Poulenc Rorer (now Sanofi) and Chugai-Rhône-Poulenc. Dr. Horobin received her medical degree from the University of Manchester, England. Dr. Horobin currently serves on the boards of Kymera Therapeutics and Nordic Nanovector ASA. Dr. Horobin has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K and was not appointed pursuant to any arrangement or understanding between Dr. Horobin and any other person.

What is the salary of Joanna Horobin?

As the Independent Director of Liquidia Corp, the total compensation of Joanna Horobin at Liquidia Corp is $57,450. There are 11 executives at Liquidia Corp getting paid more, with Neal Fowler having the highest compensation of $1,729,090.

How old is Joanna Horobin?

Joanna Horobin is 65, he's been the Independent Director of Liquidia Corp since 2019. There are 3 older and 17 younger executives at Liquidia Corp. The oldest executive at Liquidia Corp is Ralph Snyderman, 80, who is the Independent Director.

What's Joanna Horobin's mailing address?

Joanna's mailing address filed with the SEC is 419 DAVIS DRIVE, SUITE 100, , MORRISVILLE, NC, 27560.

Insiders trading at Liquidia Corp

Over the last 6 years, insiders at Liquidia Corp have traded over $16,750,945 worth of Liquidia Corp stock and bought 12,456,625 units worth $100,694,400 . The most active insiders traders include Forest Baskett, Scott D Sandell und Peter J Barris. On average, Liquidia Corp executives and independent directors trade stock every 18 days with the average trade being worth of $1,467,274. The most recent stock trade was executed by Russell Schundler on 30 August 2024, trading 2,344 units of LQDA stock currently worth $23,792.

What does Liquidia Corp do?

liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.

Complete history of Joanna Horobin stock trades at Idera Pharmaceuticals, Verastem Inc, Liquidia Corp und Kymera Therapeutics

Liquidia Corp executives and stock owners

Liquidia Corp executives and other stock owners filed with the SEC include:

• Neal Fowler,
  Chief Executive Officer and Director
• Robert Lippe,
  Chief Operations Officer
• Robert A. Lippe,
  Chief Operations Officer
• Dr. Tushar Shah M.D.,
  Sr. VP of Product Devel. & Chief Medical Officer
• Damian deGoa,
  CEO & Director
• Stephen Bloch,
  Independent Chairman of the board
• Ralph Snyderman,
  Independent Director
• Raman Singh,
  Independent Director
• Seth Rudnick,
  Independent Director
• Arthur Kirsch,
  Independent Director
• Katherine Rielly-Gauvin,
  Independent Director
• Joanna Horobin,
  Independent Director
• Dr. Roger A. Jeffs Ph.D.,
  CEO & Director
• Tushar Shah,
  Chief Medical Officer
• Jeri Thomas,
  Senior Vice President - Commercial
• Robert Roscigno,
  Senior Vice President - Product Development
• Benjamin Maynor,
  Senior Vice President - Research & Development
• Steven Bariahtaris,
  Interim Chief Financial Officer
• Celia Reyes-Hoke,
  VP of People & Culture
• Scott Moomaw,
  Sr. VP of Commercial
• Jason Adair,
  Sr. VP of Corp. Devel. & Strategy
• Russell Schundler,
  Gen. Counsel & Corp. Sec.
• Jennifer Almond,
  Director of Investor Relations & Corp. Communications
• Michael Kaseta,
  Chief Financial Officer
• Dr. Ginger Denison,
  Co-Founder
• William R. Kenan Jr.,
  Co-Founder
• Partners Lpjohnson David Ed...,
  
• Ventures, Llceshelman Fredr...,
  
• Damian De Goa,
  Director
• Kevin K Gordon,
  President and CFO
• Edward T Mathers,
  Director
• Timothy Albury,
  SVP, Chief Accounting Officer
• Lt Ltd Zahir Fares Xeraya,
  
• Peter J Barris,
  10% owner
• M James Barrett,
  10% owner
• & Melinda Gates Foundation ...,
  
• Group Iv, Llc Wakefield,
  10% owner
• Group Iii, Llc Wakefield,
  10% owner
• Venture Investments Ltd Mor...,
  10% owner
• Product Development, Llc Wi...,
  
• Viii Lp Canaan Partners Vii...,
  
• Group Pte Ltdvorobyev Maxim...,
  
• Capital Spc Ltdal Wealth Pa...,
  
• Scott D Sandell,
  10% owner
• Patrick J Kerins,
  10% owner
• Forest Baskett,
  10% owner
• East Ltd Bathurst Enterpris...,
  
• Plc Gsk,
  
• Enterprise Associates 12, L...,
  
• Of North Carolina At Chapel...,
  10% owner
• Capital Ii, Lp Sovereign's,
  10% owner
• Revelation Healthcare Fund ...,
  
• Family Credit Llc Series D ...,
  
• Mutual Holdings, Inc. Medical,
  10% owner
• Arthur Ma.M. Pappas Life Sc...,
  
• Ltd Bathurst Enterprises Lt...,
  
• David Edward Johnson,
  Director
• Shawn Glidden,
  VP,Legal Affairs and Secretary
• Richard D Katz,
  Chief Financial Officer
• David Edward Caligan Partne...,
  
• Michael Kaseta,
  CFO and COO
• Florina Krawchick,
  SVP, Human Resources
• Rajeev Saggar,
  Chief Medical Officer
• Scott Moomaw,
  Chief Commercial Officer
• Roger Jeffs,
  Chief Executive Officer
• Russell Schundler,
  General Counsel
• Paul B Manning,
  Director
• Jason Adair,
  Chief Business Officer